Quattro Financial Advisors LLC Has $339,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Quattro Financial Advisors LLC boosted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 7,362.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,000 shares of the company’s stock after purchasing an additional 4,933 shares during the quarter. Quattro Financial Advisors LLC’s holdings in AstraZeneca were worth $339,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Cerity Partners LLC grew its stake in AstraZeneca by 113.0% in the fourth quarter. Cerity Partners LLC now owns 95,677 shares of the company’s stock valued at $6,444,000 after acquiring an additional 50,750 shares during the period. Raymond James Financial Services Advisors Inc. increased its stake in AstraZeneca by 43.7% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 163,011 shares of the company’s stock worth $10,979,000 after purchasing an additional 49,541 shares in the last quarter. Assetmark Inc. raised its holdings in AstraZeneca by 11.2% during the 4th quarter. Assetmark Inc. now owns 154,906 shares of the company’s stock worth $10,433,000 after buying an additional 15,642 shares during the period. Manning & Napier Group LLC lifted its stake in AstraZeneca by 281.2% in the fourth quarter. Manning & Napier Group LLC now owns 2,779,212 shares of the company’s stock valued at $187,180,000 after buying an additional 2,050,064 shares in the last quarter. Finally, International Assets Investment Management LLC bought a new stake in shares of AstraZeneca during the fourth quarter worth $10,395,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Price Performance

Shares of NASDAQ:AZN traded down $0.95 during midday trading on Tuesday, hitting $76.99. The stock had a trading volume of 3,215,465 shares, compared to its average volume of 5,548,286. The company has a quick ratio of 0.70, a current ratio of 0.89 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $238.71 billion, a P/E ratio of 38.21, a price-to-earnings-growth ratio of 1.40 and a beta of 0.45. The company’s 50-day moving average price is $77.68 and its 200-day moving average price is $70.51. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $80.86.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Thursday, April 25th. The company reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.08. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. The firm had revenue of $12.68 billion for the quarter, compared to the consensus estimate of $11.92 billion. As a group, equities research analysts predict that AstraZeneca PLC will post 4.04 EPS for the current fiscal year.

Analyst Ratings Changes

AZN has been the subject of a number of research analyst reports. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. BMO Capital Markets boosted their price objective on shares of AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research report on Friday, April 26th. Barclays raised shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Finally, The Goldman Sachs Group assumed coverage on shares of AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $88.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.